Efficacy and safety of sequential moxifloxacin for treatment of community-acquired pneumonia associated with atypical pathogens

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 23, Issue 10, 2004, Pages 772-775

  Hoeffken, G ^a   Talan, D ^b   Larsen, L S ^c   Peloquin, S ^d   Choudhri, S H ^e   Haverstock, D ^e   Jackson, P ^e   Church, D ^e  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b UCLA MEDICAL CENTER   (United States)

^c Fusion Clinical Trials   (United States)

^d Hospital Fleury   (Canada)

^e BAYER CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALATROFLOXACIN; AMOXICILLIN PLUS CLAVULANIC ACID; BETA LACTAM ANTIBIOTIC; CLARITHROMYCIN; LEVOFLOXACIN; MACROLIDE; MOXIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TROVAFLOXACIN;

ADULT; ARTICLE; BACTERIOLOGY; CHLAMYDOPHILA PNEUMONIAE; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; LEGIONELLA PNEUMOPHILA; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MICROBIOLOGY; MULTICENTER STUDY; MYCOPLASMA PNEUMONIAE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-INFECTIVE AGENTS; AZA COMPOUNDS; COMMUNITY-ACQUIRED INFECTIONS; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; PNEUMONIA, BACTERIAL; QUINOLINES; RETROSPECTIVE STUDIES;

EID: 8744257509     PISSN: 09349723     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10096-004-1214-5     Document Type: Article

References (15)

1. Plouffe JF (2000) Importance of atypical pathogens of community-acquired pneumonia. Clin Infect Dis 31(Suppl 2):35-39
2. File TM Jr, Tan JS, Plouffe JF (1998) The role of atypical pathogens: Mycoplasma pneumoniae, Chlamydia pneumoniae, and Legionella pneumophila in respiratory infection. Infect Dis Clin North Am 12:569-592
3. Lim WS, Macfarlane JT, Boswell TC, Harrison TG, Rose D, Leinonen M, Saikku P (2001) Study of community acquired pneumonia aetiology (SCAPA) in adults admitted to hospital: implications for management guidelines. Thorax 56:296-301
4. Ruiz-Gonzalez A, Falguera M, Nogues A, Rubio-Caballero M (1999) Is Streptococcus pneumoniae the leading cause of pneumonia of unknown etiology? A microbiologic study of lung aspirates in consecutive patients with community-acquired pneumonia. Am J Med 106:385-390
5. Porath A, Schlaeffer F, Lieberman D (1997) The epidemiology of community-acquired pneumonia among hospitalized adults. J Infect 34:41-48
6. Marrie TJ, Peeling RW, Fine MJ, Singer DE, Coley CM, Kapoor WN (1996) Ambulatory patients with community-acquired pneumonia: the frequency of atypical agents and clinical course. Am J Med 101:508-515
7. Marston BJ, Plouffe JF, File TM Jr et al (1997) Incidence of community-acquired pneumonia requiring hospitalization: results of a population-based active surveillance study in Ohio. Community-Based Pneumonia Incidence Study Group. Arch Intern Med 157:1709-1718
8. Mandel LA (2000) Guidelines for community-acquired pneumonia: a tale of 2 countries. Clin Infect Dis 31:422-425
9. Mandell LA, Bartlett JG, Dowell SF, File TM Jr, Musher DM, Whitney C, Infectious Diseases Society of America (2003) Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. Clin Infect Dis 37:1405-1433
10. Niederman MS, Mandell LA, Anzueto A et al (2001) Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med 163:1730-1754
11. Finch R, Schurmann D, Collins O et al (2002) A randomized controlled trial of sequential intravenous (IV) and oral moxifloxacin compared with sequential FV and oral co-amoxiclav with or without clarithromycin in patients with community-acquired pneumonia requiring initial parenteral treatment. Antimicrob Agents Chemother 46:1746-1754
12. File TM, Larsen LS, Fogarty CM et al (2001) Safety and efficacy of sequential (FV to PO) moxifloxacin for the treatment of community-acquired pneumonia in hospitalized patients. Todays Ther Trends 19:251-270
13. Niederman MS, Bass JB, Campbell GD et al (1993) Guidelines for the initial management of adults with community-acquired pneumonia: diagnosis, assessment of severity, and initial antimicrobial therapy. Am Rev Respir Dis 148:1418-1426
14. Norrby SR, Petermann W, Willcox PA et al (1998) A comparative study of levofloxacin and ceftriaxone in the treatment of hospitalized patients with pneumonia. Scand J Infect Dis 30:397-404
15. Ruiz M, Ewig S, Torres A et al (1999) Severe community-acquired pneumonia. Risk factors and follow-up epidemiology. Am J Respir Crit Care Med 160:923-929